In samples tested for ALK IHC expression (n=1052), there was an increased proportion of ALK IHC expression in HR+ NSCLC compared with HR- (10/163, 6.13% vs. 21/889, 2.36%, p = 0.0190, q =0.0434). Here, ALK is linked to non-small cell lung carcinoma.